title: Rationale for RAS mutation-tailored therapies.
abstract: RAS mutations are among the most common genetic alterations found in cancerous tumors but rational criteria or strategies for targeting RAS-dependent tumors are only recently emerging. Clinical and laboratory data suggest that patient selection based on specific RAS mutations will be an essential component of these strategies. A thorough understanding of the biochemical and structural properties of mutant RAS proteins form the theoretical basis for these approaches. Direct inhibition of KRAS G12C by covalent inhibitors is a notable recent example of the RAS mutation-tailored approach that establishes a paradigm for other RAS mutation-centered strategies.
authors.affiliation: School of Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
authors.forename: Steven K
authors.initials: SK
authors.lastname: Montalvo
authors.affiliation: Departments of Biochemistry & Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
authors.forename: Lianbo
authors.initials: L
authors.lastname: Li
authors.affiliation: Departments of Biochemistry & Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
authors.forename: Kenneth D
authors.initials: KD
authors.lastname: Westover
mesh_terms: D000483:Alleles; D002471:Cell Transformation, Neoplastic / Q000235:genetics / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic; D005838:Genotype; D006801:Humans; D058990:Molecular Targeted Therapy; D009154:Mutation; D009369:Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000401:mortality / Q000628:therapy*; D063868:Patient Outcome Assessment; D011379:Prognosis; D020033:Protein Isoforms; D018631:ras Proteins / Q000235:genetics* / Q000378:metabolism
chemical_list: D020033:Protein Isoforms; D018631:ras Proteins
keywords: GTPase; RAS; cancer; isoforms